Skip to content
Medical Health Aged Care

neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer

neurocare group 3 mins read

neurocare group AG, a best practice platform for mental health and performance, is pleased to announce the appointment of Kevin Reeder as Chief Financial Officer of the company, from January 1st 2025.

MUNICH, GERMANY / ACCESSWIRE / November 21, 2024 / neurocare group AG ("neurocare" or the "Company"), a best practice platform for mental health and performance, is pleased to announce the appointment of Kevin Reeder as Chief Financial Officer of the company, from January 1st 2025.

neurocare appoints Kevin Reeder as CFO starting January 2025
neurocare appoints Kevin Reeder as CFO starting January 2025

Kevin Reeder holds an MBA from Oxford University and is currently the CEO of the venture capital firm bm|t, one of neurocare´s largest investors. Kevin has a long history in international investment management both in the US and in Europe, spanning venture capital, private equity, and publicly traded investments.

Prior to joining bm|t, Kevin held key roles at INVESCO, Silvergate Capital, GVO Asset Management, and Bank am Bellevue. He also gained experience outside of the investment sector as Head of Data and Credit at M-KOPA, a high-growth company in Africa, where he led fundraising efforts, managed financial operations, and established the company's data analytics platform.

Kevin joined the neurocare board at the end of 2021 and played a key role in fundraising, strategy, and M&A. He will step aside from the board to fully focus on his responsibilities as CFO, driving financial strategy and supporting neurocare's growth initiatives.

"We are delighted to welcome Kevin Reeder as neurocare's new CFO. Having worked with Kevin since joining the board, I have developed a deep respect and admiration for him as a business leader who understands our business and vision. Kevin's exceptional expertise and longstanding familiarity with neurocare's goals make him an ideal fit to help drive our growth and deliver value to our stakeholders," said Tristan de Boysson, Chairman of the Supervisory Board.

"Kevin's appointment as CFO completes neurocare's Global Leadership Team at a time of such exciting growth for our innovative company," said Thomas Mechtersheimer, Founder & CEO of neurocare. "Having worked closely with Kevin as a Board member, I am confident that his deep understanding of our business will enable us to drive neurocare's growth faster right away. On a personal note, I am much looking forward to sharing my life's professional vision and purpose with someone so energetic and equally purpose driven."

"I am honored to step into the role of CFO at neurocare and to be part of such a forward-thinking company dedicated to transforming mental health and performance," said Kevin Reeder. "Having had the privilege of working with neurocare as a Board member, I have a deep appreciation for the team's vision and the positive impact we're making. I look forward to leveraging my experience to support neurocare's growth and financial strategy as we continue to expand our reach and become a global leader in mental healthcare."

Contact Information:

Sally Remington
Global Marketing Manager
[email protected]
+49 152 2305 8385

SOURCE: neurocare group AG

.

View the original press release on newswire.com.

More from this category

  • Business Company News, Medical Health Aged Care
  • 12/02/2026
  • 09:37
I-screen - an Australian-founded health technology company

Former AWS and Accenture AI Leader Joins Australian Healthtech i-screen as AI Push Accelerates

Key points High-profile global AI executive appointment signals next growth phase for Australian healthtech Brad Ryan appointed Chief AI Officer – Former AWS APJ Data & AI Partner Lead and Accenture Managing Director with 30+ years technology leadership experience Platform scale now approaching 1 million diagnostic tests across four countries Singapore expansion positions i-screen as a regional AI-driven preventive health player AI investment focused on earlier detection, personalised screening and longevity insights Australian-founded health technology company i-screen has appointed senior global technology executive Brad Ryan,GAICD, as Chief AI Officer, strengthening its leadership team as the business deepens its investment in…

  • Contains:
  • Government Federal, Medical Health Aged Care
  • 12/02/2026
  • 09:29
Private Healthcare Australia

Health funds back stronger transparency laws for specialist doctor fees

Private Healthcare Australia has welcomed the Federal Government’s legislation to upgrade the Medical Costs Finder website, saying it is a critical step toward tackling Australia’s growing specialist fee crisis. The reform will expand the information available about specialist doctors’ fees, allowing patients to compare typical costs before booking an appointment and better estimate their likely out-of-pocket expenses. The move comes after PHA last week released its report, Restoring affordable access to specialist care in Australia, backed by a nationally representative survey of more than 4,000 Australians. The report revealed an urgent affordability and access problem reshaping Australia’s health system. It…

  • Medical Health Aged Care
  • 12/02/2026
  • 09:00
Monash University

Monash University publishes a world first clinical practice guideline for the appropriate use of psychedelics

A new Australian Clinical Practice Guideline for the Appropriate Use of Methylenedioxymethamphetamine-assisted psychotherapy (MDMA-AP) for Post-Traumatic Stress Disorder (PTSD) has been approved by the National Health and Medical Research Council (NHMRC). The Guideline is the world’s first related to MDMA-AP to be developed using the gold standard Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. In 2023, Australia became the first country to reschedule MDMA from a Prohibited Substance (Schedule 9) to a Controlled Substance (Schedule 8) for the treatment of PTSD. This has allowed authorised psychiatrists to administer MDMA for the treatment of PTSD outside of clinical trials.…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.